<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734240</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 353512 CS1</org_study_id>
    <nct_id>NCT00734240</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers</brief_title>
  <official_title>Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single and multiple
      doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512
      from the blood, and to evaluate the effectiveness of ISIS 353512 in lowering a protein in the
      blood associated with inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 1, double blind, placebo-controlled, dose-escalation study conducted at
      a single center to 1)evaluate the safety and tolerability of single and multiple doses of
      ISIS 353512 administered intravenously and subcutaneously, 2)evaluate the pharmacokinetic
      profile of single and multiple doses of ISIS 353512 administered intravenously and
      subcutaneously, and 3)evaluate the pharmacodynamics of ISIS 353512 in lowering constitutive
      levels of c-reactive proteins in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single and multiple doses of ISIS 353512 administered intravenously and subcutaneously.</measure>
    <time_frame>14 Days post treatment of each cohort</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic profile of single and multiple doses of ISIS 353512 administered intravenously and subcutaneously.</measure>
    <time_frame>14 Days post treatment of each cohort</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacodynamics of ISIS 353512 administered intravenously and subcutaneously.</measure>
    <time_frame>14 Days post treatment of each cohort</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F (100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Titration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Titration 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>50 mg via 2 hour IV infusion, single dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>50 mg via 2 hour IV infusion, 6 doses over 22 days</description>
    <arm_group_label>AA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>50 mg via SC injection, single dose</description>
    <arm_group_label>G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>50 mg via SC injection, 6 doses over 22 days</description>
    <arm_group_label>GG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8</description>
    <arm_group_label>Dose-Titration 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>100 mg via 2 hour IV infusion, single dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>200 mg via 2 hour IV infusion, single dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>100 mg via SC injection, single dose</description>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>200 mg via SC injection, single-dose</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>100 mg via 2 hour IV infusion, 6 doses over 22 days</description>
    <arm_group_label>BB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>200 mg via 2 hour IV infusion, 6 doses over 22 days</description>
    <arm_group_label>CC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>100 mg via SC injection, 6 doses over 22 days</description>
    <arm_group_label>HH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>200 mg via SC injection, 6 doses over 22 days</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo</description>
    <arm_group_label>F (100 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid</description>
    <arm_group_label>F (200 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 353512</intervention_name>
    <description>2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8</description>
    <arm_group_label>Dose-Titration 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 55 years

          -  Male or female although females must be post-menopausal or surgically sterile

          -  In good health

          -  BMI &lt; 32 kg/m2

          -  Give written informed consent to participate in the study

          -  hsCRP at Screening ≥ 0.50 mg/L and ≤ 5.0 mg/L (for 2 measurements ≥ 2 weeks apart;
             with difference between measurements ≤ 2.5 mg/L)(Multiple Dose Subjects only, not
             including dose-titration cohorts)

        Exclusion Criteria:

          -  Pregnant women, nursing mothers or women of childbearing potential

          -  Clinically significant abnormalities in medical history or physical examination

          -  Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood
             pressure &lt; 90 mm Hg or &gt; 140 mm Hg, diastolic blood pressure &lt; 50 mm Hg or &gt; 90 mm Hg
             or heat rate &lt; 50 or &gt; 100 bpm) at Screening

          -  Clinically significant abnormalities on laboratory examination, other than hsCRP

          -  Clinically significant abnormalities in coagulation parameters

          -  Positive test for HIV, TB (PPD test) or hepatitis B or C at Screening

          -  History of latent or active tuberculosis or exposure to endemic areas within 8 weeks
             prior to PPD test at Screening

          -  History of positive PPD test or positive PPD test result (≥ 5 mm) indicating possible
             tuberculosis infection

          -  Fasting triglycerides &gt; 400 mg/dL at Screening

          -  Malignancy (with the exception of basal or squamous cell carcinoma of the skin if
             adequately treated and no recurrence for &gt; 1 year)

          -  Evidence of ongoing chronic inflammatory condition or infection

          -  Any other concurrent condition which, in the opinion of the Investigator, would
             preclude participation in this study or interfere with compliance

          -  Regular use of alcohol within 6 months prior to Screening (&gt; 14 units of alcohol per
             week; 1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol)

          -  Use of soft drugs (such as marijuana) within 3 months prior to Screening or hard drugs
             (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to Screening, or
             positive urine drug screen at Screening

          -  Smoking &gt; 10 cigarettes per day

          -  Use of an investigational drug or participation in an investigational study involving
             a small molecule with 30 days prior to dosing or participation in an investigational
             study involving biologic compounds within 90 days prior to dosing

          -  Regularly taking OTC medications and/or vitamin supplements that may alter CRP, e.g.,
             NSAIDs, aspirin, vitamin E, fish oil, within 14 days prior to Screening

          -  Receiving prescription medications, including hormone replacement therapy, statins,
             TNF-α inhibitors, or other anti-inflammatory or immunosuppressive drugs within 30 days
             prior to Screening

          -  Immunization with a live attenuated vaccine one month prior to dosing or planned
             vaccination during the course of the study

          -  Blood donation of 50 to 499 mL within 30 days of Screening or of &gt; 499 mL within 60
             days of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>July 28, 2010</last_update_submitted>
  <last_update_submitted_qc>July 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Isis Pharmaceuticals, Inc.</name_title>
    <organization>Isis Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

